Abstract： Objective： To observe the effect of Tongxinluo capsules combined with alprostadil and nicorandil on myocardial injury and blood lipid levels in patients with acute coronary syndrome(ACS) after percutaneous coronary intervention (PCI). Methods：A total of 120 cases of ACS patients were selected and randomly divided into the control group and the study group， 60 cases in each group. Both groups were given routine treatment； the control group was additionally given alprostadil and nicorandil， and the study group was additionally given Tongxinluo capsules based on the treatment of the control group. The clinical effect and the changes in myocardial injury markers and blood lipid levels in the two groups were compared. Results： In 24 hours after PCI， the levels of cardiac troponin I(cTnI)， creatine kinase- MB(CK- MB) in the two groups were increased when compared with those before treatment(P＜0.05)；the levels of cTnI and CK- MB in the study group were lower than those in the control group(P＜0.05). After treatment，the levels of total cholesterol(TC)，low-density lipoprotein cholesterol(LDL- C)， triglyceride(TG) in the two groups were decreased when compared with those before treatment(P＜0.05)， and the levels of high density lipoprotein cholesterol(HDL- C) were increased(P＜0.05)； the levels of TC，LDL- C and TG in the study group were lower than those in the control group(P＜0.05)，and the level of HDL- C was higher(P＜0.05). The total incidence of cardiovascular adverse events was 6.67% in the study group，significantly lower than that of 23.33% in the control group(P＜0.05). Conclusion：The therapy of Tongxinluo capsules combined with alprostadil and nicorandil has significant curative effect in treating ACS patients undergoing PCI，which can not only effectively regulate the lipid metabolism and reduce the degree of myocardial injury，but also help to reduce the risk of cardiovascular adverse events.